Business & MarketsCompanies

GSK to Buy IDRx for $1.15 Billion as Mergers and Acquisitions Pick Up Steam in 2025

IDRx is a clinical-stage company that develops intelligently designed precision therapies for treating gastrointestinal stromal tumors.
Save
GSK to Buy IDRx for $1.15 Billion as Mergers and Acquisitions Pick Up Steam in 2025
The logo of the British multinational pharmaceutical company GlaxoSmithKline on top of its headquarters in London on Feb. 2, 2022. Justin Tallis/AFP via Getty Images
Panos Mourdoukoutas
Updated:
0:00
Business Analysis

The year 2025 may turn out to be a good one for mergers and acquisitions (M&A). Two weeks into the new year, merger activity is picking up steam. After the surprise announcement of the mergers between JCPenney and Sparc Group and between Constellation and Calpine last week, GSK and IDRx followed suit on Jan. 13, adding cheer to otherwise gloomy financial markets.

Panos Mourdoukoutas
Panos Mourdoukoutas
Author
Panos Mourdoukoutas is a professor of economics at Long Island University in New York City. He also teaches security analysis at Columbia University. He’s been published in professional journals and magazines, including Forbes, Investopedia, Barron's, IBT, and Journal of Financial Research. He’s also the author of many books, including “Business Strategy in a Semiglobal Economy” and “China's Challenge.”